エンドウ　シュンジ   Shunji Endo   遠藤　俊治    所属   川崎医科大学  医学部 臨床医学　消化器外科学    職種   准教授
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202.
掲載誌名	正式名：Anticancer research 略　 称：Anticancer Res ISSNコード：17917530/02507005
掲載区分	国外
巻・号・頁	39(2),pp.1059-1065
著者・共著者	Endo Shunji, Kurokawa Yukinori, Gamoh Makio, Kimura Yutaka, Matsuyama Jin, Taniguchi Hirokazu, Takeno Atsushi, Kawabata Ryohei, Kawada Junji, Masuzawa Toru, Yamamoto Kazuyoshi, Kobayashi Kouji, Sakai Daisuke, Shimokawa Toshio, Satoh Taroh
担当区分	筆頭著者
発行年月	2019/02
概要	BACKGROUND/AIM:Trastuzumab with S-1 plus cisplatin was proved to be effective for human epidermal growth factor receptor type 2 (HER2)-positive advanced gastric cancer with measurable lesions. However, the efficacy and safety of this regimen in the absence of measurable lesions are unknown.PATIENTS AND METHODS:Patients with HER2-positive gastric cancer without measurable lesions received cisplatin plus trastuzumab intravenously on day 1 and oral S-1 on days 1-14 of a 21-day cycle. The primary end-point was overall survival, and 40 patients were planned to be enrolled.RESULTS:Fifteen patients were enrolled. The median overall survival was 14.4 months. The 1- and 3-year overall survival rates were 66.7 % and 26.7 %, respectively. Major grade 3-4 adverse events included neutropenia (47%), anemia (40%), diarrhea (20%), nausea (20%), and anorexia (20%).CONCLUSION:Trastuzumab with S-1 plus cisplatin might be effective and tolerable for HER2-positive advanced gastric cancer without measurable lesions.
DOI	10.21873/anticanres.13213
PMID	30711995